Investor Overview

SurModics, Inc. is a leading provider of surface modification, drug delivery, and in vitro diagnostic technologies to the healthcare industry. Our mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. SurModics partners with many of the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment.

We are customer-focused and depend on continuous innovation to drive a business model which is primarily based on revenue generated through technology licenses. Through our technologies, our healthcare industry customers develop improved products or products with new functionality. Our core offerings include medical device hydrophilic coating technologies and in vitro diagnostic immunoassay reagents. Our strategy is to build on our product and technical leadership within these fields, and expand our core offerings to provide us with opportunities for longer term susta... More >>

Date Title   05/21/13 SurModics to Present at the Jefferies Global Healthcare Conference Webcast is Live on Monday, June 3, at 2:30 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May. 21, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community...  05/07/13 SurModics Reports Second Quarter Fiscal 2013 Results GAAP Revenue Grows 12% Continuing Operations GAAP EPS Increases to $0.23 Non-GAAP Continuing Operations EPS Increases 25% to $0.20 Revenue and EPS Ranges for Full Year Reaffirmed EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May. 7, 2013-- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announ...  04/30/13 SurModics to Webcast Second Quarter 2013 Earnings Conference Call on May 7 Webcast is Live at 4:00 p.m. (CT) EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Apr. 30, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its second quarter 2013 conference call on Tuesday, May 7, at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that...  02/11/13 SurModics' New Low Friction, Low Particulate Device Coatings Introduced SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 11, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™ lubricious coatings for endovascular medical devices. Serene coatings are a breakthrough technology that delivers lubricity and durability w...